Artificial Trachea Researcher Found Guilty of Misconduct

An independent investigator says that the surgeon misrepresented the truth in papers about artificial trachea transplants.

Written byBob Grant
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

An artificial trachea, similar to those transplanted by Macchiarini, made by seeding an inorganic scaffold with stem cellsUCLSurgeon Paolo Macchiarini, who transplanted artificial tracheae into several patients, has been found guilty of research misconduct. In a report submitted last week (May 13), an independent investigator, Bengt Gerdin of Uppsala University in Sweden, said that Macchiarini’s papers describing the process of growing and implanting tracheae in three patients did not mesh with hospital records. “There were data in the papers that could not be found in the medical records,” Gerdin told ScienceInsider. The discrepancies constitute “a systemic misrepresentation of the truth that lead the reader to have a completely false impression of the success of the technique,” he said.

Macchiarini, who is a visiting professor at the Karolinska Institute in Stockholm, made headlines in 2012 when he was arrested and charged with fraud and attempted extortion in his native Italy. This led to retractions of some of his published work. Before that, in 2011, Pierre Delaere of UZ Leuven in Belgium accused Macchiarini of trumping up research findings in several papers reporting the results of his artificial trachea work published in The Lancet. These accusations came to light last year, when Delaere lodged a formal complaint, and Karolinska officials began an internal investigation of the misconduct claims.

But last month, members of Karolinska’s ethics council conducting that internal investigation cleared Macchiarini of misconduct in those instances.

Gerdin’s external investigation, however, involved separate misconduct allegations ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies